^
Association details:
| Biomarker: | IKZF1 deletion |
|---|---|
| Cancer: | B Acute Lymphoblastic Leukemia |
| Drug Class: | CD19-targeted CAR-T immunotherapy |
| Direction: | Resistant |
Evidence:
Source:
Title:
IMPACT OF IKZF1 DELETION IN RELAPSED AND/OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH CD19-CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY
Published date:
05/11/2023
Excerpt:
In a multivariable Cox regression model adjusting for factors contributing to event-free survival, including Ph status, immunophenotype, and chromosome karyotype, IKZF1 deletion remained independently associated with inferior event-free survival...IKZF1 deletion is a potent tumor-intrinsic biomarker that can inform risk stratification and clinical trial design inpatients with B-ALL treated with CD19-CAR-T.
